The COCOON study reveals a new dermatology management strategy that significantly reduces skin-related adverse effects in patients with lung cancer patients undergoing treatment with amivantamab and lazertinib.
Byoung Chul Cho, MD, PhD
Byoung Chul Cho, MD, PhD, is a medical oncologist at Yonsei Cancer Center in South Korea.
Articles by Byoung Chul Cho, MD, PhD
Byoung Chul Cho, MD, PhD, discusses the implications of the CHRYSALIS-2 study of amivantamab and lazertinib.